

March 31, 2021

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 001 Scrip Code: 512529	National Stock Exchange of India Limited Listing Department Exchange Plaza, Bandra-Kurla Complex Bandra (East) Mumbai – 400 051 Symbol: SEQUENT
--	---

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Consolidation of Shareholding in Fendigo SA, Belgium to make Fendigo SA a Wholly Owned Subsidiary of the Company

Please find attached disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, consequent to acquisition of 7.5% stake from Mr. Bernard Bradfer in Fendigo SA through Alivira Animal Health Limited, Ireland, Wholly Owned Subsidiary of the Company.

Consequent to the above acquisition, Fendigo SA has become a Wholly Owned Subsidiary of the Company.

We request you to take the above on your record.

Thanking you,

Yours faithfully,
For **Sequent Scientific Limited**



Krunal Shah
Company Secretary & Compliance Officer



SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Acquisition of Incremental Stake of 7.5% in a Fendigo SA, a subsidiary of the Company

Sr. No	Particulars	
1.	Name of the Target entity, details in brief such as size, turnover etc.	<p>Name of the Target Company:</p> <p>FENDIGOSA</p> <p>Details of Target Company:</p> <p>Fendigo SA, located at Belgium, is a trading and distribution arm for animal health products.</p> <p>FY 2019-20 Financials (€ in Thousands):</p> <p>Sales: 9,116 EBIDTA: 984 Net Profit: 673 Net Cash: 326</p>
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	No
3.	Industry to which Target entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition	<p>The object of acquisition is to consolidate the Shareholding in Fendigo SA.</p> <p>The Company was holding 92.5% stake in Fendigo SA and consequent to this acquisition, Fendigo SA has become a Wholly Owned Subsidiary of the Company.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No
6.	Indicative time period for completion	Agreement signed and Acquisition completed on March 31, 2021
7.	Nature of consideration	Cash

Krishab



8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	The Company has acquired 7.5% stake in Fendigo SA through Alivira Animal Health Limited, Ireland, Wholly Owned Subsidiary of the Company	
9.	Cost of acquisition or the price at which the shares are acquired	€551075 (Five Hundred and Fifty-One Thousand Seventy-Five euro)	
10.			
a.	Products/line of business acquired	<p>Brief Background:</p> <p>Fendigo is a veterinary pharmaceutical Company operating in the Benelux region. The Company is involved in sales and marketing of veterinary and health products for pets, farm animals, Horses, and poultry. By a wide portfolio of products Fendigo responds to the actual needs of veterinarians, farmers, and other parties of the Animal Health Sector.</p> <p>Line of Business: Pharmaceuticals</p>	
b.	Date of incorporation	20-11-1995	
c.	History of last 3 years turnover (€ in thousands)	FY 2019-20	9116
		FY 2018-19	7916
		FY 2017-18	7526
d.	Country in which the acquired entity has presence	Belgium	

Krishab

